<DOC>
	<DOCNO>NCT00979953</DOCNO>
	<brief_summary>The purpose study determine efficacy ADL5859 versus placebo ADL5747 versus placebo relieve pain participant osteoarthritis knee .</brief_summary>
	<brief_title>Efficacy Safety Study Evaluating ADL5859 ADL5747 Participants With Pain Due Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Key man woman 18 75 year age , inclusive woman childbearing potential , use insertable , injectable , transdermal , combination oral contraceptive deem highly effective United States Food Drug Administration first dose study medication end study negative finding pregnancy test perform screen randomization ( woman surgically sterile [ example , hysterectomy , tubal ligation ] postmenopausal [ ≥55 year old , menses least 2 year ; &lt; 55 year old , folliclestimulating hormone concentration within postmenopausal range &gt; 40 milliinternational unit per milliliter ( mIU/mL ) 17 βestradiol level &lt; 37 picograms per milliliter ( pg/mL ) ] also eligible participate ) male participant , surgically sterile agree use appropriate method contraception ( , use barrier method conjunction spermicide sexual partner surgically sterile , postmenopausal , use insertable , injectable , transdermal , combination oral contraceptive deem highly effective United States Food Drug Administration ) first dose study medication end study body weight 45 150 kilogram ( kg ) , inclusive pain index knee least past 6 month meet follow criterion osteoarthritis knee establish American College Rheumatology ( radiograph must take within last year ; none available , radiograph must take diagnostic criterion must confirm participant enrol study ) : index knee pain plus least 1 moderate definite osteophyte radiograph . Must also least 1 follow : 50 year old , morning stiffness le 30 minute , crepitus active motion average weekly pain score least 4.00 numeric pain rating scale ( NPRS ) index knee baseline week randomization ( eligible randomization , participant must report NPRS score via interactive voiceresponse system ( IVRS ) least 4 7 day immediately randomization , first score record Day 6 ) receive nonselective selective cyclooxygenase ( COX ) inhibitor , stable daily dose regimen least 4 week screen ; receive nonselective selective COX inhibitor need basis , discontinue use Day 14 ; receive angiotensinconverting enzyme ( ACE ) inhibitor , stable dose regimen least 4 week screen Key undergone arthroscopy index knee within 6 month study entry severe pain , opinion investigator , may impair assessment pain due osteoarthritis history hypersensitivity intolerance opioids ( include tramadol tapentadol ) , determine investigator sponsor 's medical monitor , history clinical manifestation significant renal , hepatic , hematologic , cardiovascular , metabolic , gastrointestinal , neurologic , psychiatric , another condition would preclude participation study affect outcome study take oral intramuscular corticosteroid within 30 day study entry ( inhaled topical corticosteroid permit ) receive intraarticular injection corticosteroid index joint within 12 week screen receive intraarticular injection hyaluronic acid index joint within 24 week screen currently take medication nonsteroidal antiinflammatory drug prescribe chronic pain ( duloxetine pregabalin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>delta opioid receptor agonist</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>pain</keyword>
</DOC>